Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus.

Autor: Taylor Meadows KR; Receptos, a wholly owned subsidiary of Celgene Corporation, San Diego, California, United States of America., Steinberg MW; Receptos, a wholly owned subsidiary of Celgene Corporation, San Diego, California, United States of America., Clemons B; Receptos, a wholly owned subsidiary of Celgene Corporation, San Diego, California, United States of America., Stokes ME; Celgene Corporation, Seattle, Washington, United States of America., Opiteck GJ; Receptos, a wholly owned subsidiary of Celgene Corporation, San Diego, California, United States of America., Peach R; Receptos, a wholly owned subsidiary of Celgene Corporation, San Diego, California, United States of America., Scott FL; Receptos, a wholly owned subsidiary of Celgene Corporation, San Diego, California, United States of America.

Publikováno v: PloS one [PLoS One] 2018 Apr 02; Vol. 13 (4), pp. e0193236. Date of Electronic Publication: 2018 Apr 02 (Print Publication: 2018).